Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG)

Abstract

Background: Sickle-cell anaemia is associated with substantial morbidity from acute complications and organ dysfunction beginning in the first year of life. Hydroxycarbamide substantially reduces episodes of pain and acute chest syndrome, admissions to hospital, and transfusions in adults with sickle-cell anaemia. We assessed the effect of hydroxycarbamide therapy on organ dysfunction and clinical complications, and examined laboratory findings and toxic effects.

Methods: This randomised trial was undertaken in 13 centres in the USA between October, 2003, and September, 2009. Eligible participants had haemoglobin SS (HbSS) or haemoglobin Sβ(0)thalassaemia, were aged 9-18 months at randomisation, and were not selected for clinical severity. Participants received liquid hydroxycarbamide, 20 mg/kg per day, or placebo for 2 years. Randomisation assignments were generated by the medical coordinating centre by a pre-decided schedule. Identical appearing and tasting formulations were used for hydroxycarbamide and placebo. Patients, caregivers, and coordinating centre staff were masked to treatment allocation. Primary study endpoints were splenic function (qualitative uptake on (99)Tc spleen scan) and renal function (glomerular filtration rate by (99m)Tc-DTPA clearance). Additional assessments included blood counts, fetal haemoglobin concentration, chemistry profiles, spleen function biomarkers, urine osmolality, neurodevelopment, transcranial Doppler ultrasonography, growth, and mutagenicity. Study visits occurred every 2-4 weeks. Analysis was by intention to treat. The trial is registered with ClinicalTrials.gov, number NCT00006400.

Findings: 96 patients received hydroxycarbamide and 97 placebo, of whom 83 patients in the hydroxycarbamide group and 84 in the placebo group completed the study. Significant differences were not seen between groups for the primary endpoints (19 of 70 patients with decreased spleen function at exit in the hydroxycarbamide group vs 28 of 74 patients in the placebo group, p=0·21; and a difference in the mean increase in DTPA glomerular filtration rate in the hydroxycarbamide group versus the placebo group of 2 mL/min per 1·73 m(2), p=0·84). Hydroxycarbamide significantly decreased pain (177 events in 62 patients vs 375 events in 75 patients in the placebo group, p=0·002) and dactylitis (24 events in 14 patients vs 123 events in 42 patients in the placebo group, p<0·0001), with some evidence for decreased acute chest syndrome, hospitalisation rates, and transfusion. Hydroxyurea increased haemoglobin and fetal haemoglobin, and decreased white blood-cell count. Toxicity was limited to mild-to-moderate neutropenia.

Interpretation: On the basis of the safety and efficacy data from this trial, hydroxycarbamide can now be considered for all very young children with sickle-cell anaemia.

Funding: The US National Heart, Lung, and Blood Institute; and the National Institute of Child Health and Human Development.

Conflict of interest statement

Conflicts of Interest

None of the authors had conflicts of interest.

Copyright © 2011 Elsevier Ltd. All rights reserved.

Figures

Figure 1

Trial Profile

Figure 2. Longitudinal changes in mean haematologic values in Hydroxyurea Group vs. Placebo Group

The Hydroxyurea group is indicated by red lines ( ); the Placebo group is indicated by blue lines (). Panels show mean values over time from initiation of study drug for Haemoglobin (Panel A), MCV (B), Haemoglobin F (C), Platelet Count (D), Absolute Neutrophil Count (E) and Absolute Reticulocyte Count (F). Blood counts were obtained every two to four weeks (although not all data points are shown), except for HbF, which was obtained every six months. The p-values were ≤0·005 for all comparisons except for platelet counts (p=0·2).

Figure 3. Cumulative probability of adverse events in Hydroxyurea Group vs. Placebo Group

The Hydroxyurea group is indicated by red lines ( ); the Placebo group by blue lines ( ). The cumulative probability curves were generated by the time to first event for acute chest syndrome (Panel A), pain (B), dactylitis (C), and transfusion (D). The differences in the events between the treatment groups were evaluated from the log-rank life test. The p-values for cumulative probability curves for ACS, pain, dactylitis, and transfusion were 0·02, 0·002, <0·001, and 0·03, respectively.